Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Our personalized cancer vaccine comprises patient tumor cells fused with autologous dendritic cells (DCs) and limits the risk of antigen escape by presenting a broad array of tumor antigens in the context of DC mediated co-stimulation. In clinical trials of hematologic malignancies patients, vaccination induced expansion of tumor-specific T cells (Tc) and led to prolonged remission in a subset of patients. Currently, we are developing a novel second-generation (2G) vaccine. Fusions are presented in the context of a unique biomatrix expressing high levels of 41BB ligand (41BBL), to further accentuate Tc activation.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Shira Orr, Marzia Capelletti, Dina Stroopinsky, Jessica Liegel, Myrna R. Nahas, Matthew Weinstock, Adam Morin, Robin Joyce, Salvia Jain, Jon E. Arnason, Donald Kufe, Jacalyn Rosenblatt, David E. Avigan Tags: 484 Source Type: research